ADmit Therapeutics has received an investment of 497.652$ from the ADDF Diagnostics Accelerator for the development of its early Alzheimer’s disease diagnostic test in blood samples. The Diagnostics Accelerator is a research initiative that seeks to accelerate the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias, and advance the development of more targeted treatments.

ADmit Therapeutics is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), which has been granted by Spanish and European grants, and has received private investments from Ship2B, GENESIS Biomed, BStartup10 and other investors since its inception at the end of 2017.

Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Some regions of the human genome conside...

by Universitat de Barcelona

Many repetitive regions of the genome have been considered “junk DNA...

Photos Stream